Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Ardelyx

< Previous 1 2 3 4 Next >
Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements
- Companies establish a research collaboration with associated options to license any resulting development candidates with the potential for up to $500 million in development and sales milestones for... 
Tickers ARDX KYKOY
From PR Newswire
Ardelyx Announces Presentation at Kidney Week 2019
Late breaking oral presentation to highlight data from AMPLIFY, the Pivotal Phase 3 Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder... 
Tickers ARDX
From PR Newswire
Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights
PHREEDOM clinical trial to read out this quarter 
Tickers ARDX
From PR Newswire
Ardelyx to Host Analyst Day in New York
Management to Review Late Stage Clinical Development and Commercial Potential in Hyperphosphatemia, Pipeline Program in Hyperkalemia and Recent Approval in IBS-C 
Tickers ARDX
From PR Newswire
Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference
Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today... 
Tickers ARDX
From PR Newswire
Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation
Approval supported by two Phase 3 trials demonstrating a statistically significant reduction in constipation and abdominal pain in adult patients with IBS-C 
Tickers ARDX
From PR Newswire
Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
The primary and all key secondary endpoints were met. 
Tickers ARDX
From PR Newswire
Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will... 
Tickers ARDX
From PR Newswire
Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
AMPLIFY clinical trial to read out 3Q19 
Tickers ARDX
From PR Newswire
Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference
Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today announced... 
Tickers ARDX
From PR Newswire
Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
Two Pivotal Phase 3 readouts in 2H 2019 
Tickers ARDX
From PR Newswire
Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors
Ardelyx, Inc. (NASDAQ: ARDX), today announced the appointment of Geoffrey A. Block, M.D., Vice President, Nephrology at Reata and former Director of Clinical Research in the Denver Nephrology Research... 
Tickers ARDX
From PR Newswire
Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
- Ardelyx's investigative agent for end-stage renal disease patients on dialysis represents first non-binder innovation to lower patients' phosphate levels, a critically important parameter that is... 
Tickers ARDX
From PR Newswire
Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights
Company is poised for two Phase 3 readouts in 2H 2019 for tenapanor in hyperphosphatemia 
Tickers ARDX
From PR Newswire
Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference
Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference... 
Tickers ARDX
From PR Newswire
Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
Ardelyx to Receive a $5 Million Milestone Payment 
Tickers ARDX KYKOY
From PR Newswire
Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C
Ardelyx, Inc. (Nasdaq: ARDX), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tenapanor for the treatment of patients with... 
Tickers ARDX
From PR Newswire
Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
Tenapanor Second Registration Trial for Hyperphosphatemia Ongoing; On-Track for Data in 2019 
Tickers ARDX
From PR Newswire
Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
Company Plans to Commence a Phase 2/3 Clinical Study Evaluating Tenapanor in Combination with Phosphate Binders 
Tickers ARDX
From PR Newswire
Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
Ardelyx, Inc. (Nasdaq: ARDX), today announced that new data from its long-term safety trial of tenapanor for irritable bowel syndrome with constipation (IBS-C), the T3MPO-3 trial, were presented this... 
Tickers ARDX
From PR Newswire
Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders
Ardelyx, Inc. (Nasdaq: ARDX), today announced that it will hold an investor event called "Renal Day" on Thursday, Oct. 11, 2018, from 8 to 10 a.m. ET in New York City. This year's event is the first of... 
Tickers ARDX
From PR Newswire
Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
Ardelyx, Inc. (Nasdaq: ARDX), today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting U.S. marketing authorization of tenapanor for... 
Tickers ARDX
From PR Newswire
Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
Ardelyx, Inc. (Nasdaq: ARDX), today announced that the novel mechanism of action for tenapanor for the treatment of hyperphosphatemia, or elevated serum phosphorus, has been published in the... 
Tickers ARDX
From PR Newswire
Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
Operating Runway Extended to Mid-2020 
Tickers ARDX
From PR Newswire
Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
Ardelyx, Inc. (NASDAQ: ARDX) today announced that it plans to report its second quarter 2018 financial results after market close on Tuesday, August 7, 2018. Management will host a conference call and... 
Tickers ARDX
From PR Newswire
Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference
Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the Jefferies Global Healthcare Conference on Tuesday,... 
Tickers ARDX
From PR Newswire
Ardelyx Announces Pricing of Public Offering of Common Stock
Ardelyx, Inc. (Nasdaq: ARDX) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $4.00 per share, before underwriting... 
Tickers ARDX
From PR Newswire
Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank
Ardelyx, Inc. (Nasdaq: ARDX), today announced it has entered into a $50.0 million senior secured term loan facility with Solar Capital Ltd. and the Life Sciences Group at Bridge Bank, a division of... 
Tickers ARDX
From PR Newswire
Ardelyx Announces Proposed Public Offering of Common Stock
Ardelyx, Inc. (Nasdaq: ARDX), today announced that it has commenced an underwritten public offering of up to $50,000,000 of shares of its common stock. All of the shares to be sold in the offering will... 
Tickers ARDX
From PR Newswire
Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights
On Track to Submit NDA for Tenapanor in IBS-C in Second Half of 2018 
Tickers ARDX
From PR Newswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.